New combo therapy takes on deadly brain cancer

NCT ID NCT06157541

Ongoing Disease control Sponsor: Queensland Institute of Medical Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a combination of donor immune cells (targeting a common virus) and the drug pembrolizumab (Keytruda) in 58 people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach can shrink tumors and help patients live longer. The study has two parts: first finding the safest dose, then checking how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donor immune cells (CMV-specific T cells) and pembrolizumab (Keytruda)
What this could lead to: If it works, this could offer a new treatment option for glioblastoma, a tough brain cancer, by helping the immune system attack tumors more effectively.
What could go wrong: This is an early-phase trial with only 58 participants, so results may not apply broadly. There are risks of side effects from the immune cells and pembrolizumab, and the combination may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, GRADE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTOMA, GRADE IV GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Austin Hospital

Heidelberg, Victoria, 3084, Australia
Newro Foundation

Bowen Hills, Queensland, 4006, Australia
Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia
Royal Brisbane and Women's Hospital

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.